Cook Jennifer E. 4

What Happened

• Jennifer E. Cook, a member of BridgeBio Pharma's Board of Directors, exercised stock options and sold common shares on June 15, 2026. She exercised 83,088 option shares (65,921 at $8.45 and 17,167 at $16.75) for a total exercise cost of $844,579, and sold 90,240 shares in open-market transactions for aggregate gross proceeds of approximately $6,012,157. The filing also reports the derivative interests being converted/ disposed in connection with the exercises.

Key Details

• Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (filed within the typical two-business-day window).
• Exercises: 65,921 shares @ $8.45 ($557,032) and 17,167 shares @ $16.75 ($287,547) — total exercised = 83,088 shares costing $844,579.
• Sales: 88,737 shares @ weighted avg $66.62 (F2) = $5,911,242; 1,503 shares @ weighted avg $67.14 (F3) = $100,915; total sales ≈ $6,012,157.
• The filing shows $0.00 for two derivative dispositions; these reflect conversion/disposition of the option interests upon exercise.
• Footnotes of note: F1 — sales were effected under a Rule 10b5-1 trading plan adopted March 16, 2026; F2/F3 — weighted-average sale price ranges with breakdown available on request; F4/F5 — vesting schedules for the reported options. Exhibit 24 (Power of Attorney) was included.
• Shares owned after the reported transactions are not disclosed in the provided filing excerpt.

Context

• This pattern — exercising options and then selling the resulting shares (reported here) — is commonly used to cover exercise costs, taxes, or to diversify; the presence of a 10b5-1 plan indicates the sales were preplanned and automated. These facts are descriptive and do not, by themselves, indicate the insider’s view on the company’s prospects.